--- title: "Sector Update: Healthcare Stocks Softer Thursday Afternoon" type: "News" locale: "en" url: "https://longbridge.com/en/news/286451601.md" description: "Healthcare stocks declined on Thursday, with the NYSE Healthcare Index down 0.1%. Biogen shares fell nearly 6% after a failed Alzheimer's trial. Prestige Consumer Healthcare reported disappointing Q4 results and lowered 2026 guidance, leading to an 8% drop in shares. Doximity's shares dropped over 24% after issuing weak guidance, despite long-term growth potential. In contrast, Aveanna Healthcare shares rose 11% following strong Q1 earnings and an increased revenue forecast for 2026." datetime: "2026-05-14T17:43:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286451601.md) - [en](https://longbridge.com/en/news/286451601.md) - [zh-HK](https://longbridge.com/zh-HK/news/286451601.md) --- # Sector Update: Healthcare Stocks Softer Thursday Afternoon 01:43 PM EDT, 05/14/2026 (MT Newswires) -- Healthcare stocks edged down Thursday afternoon, with the NYSE Healthcare Index easing 0.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) fractionally lower. The iShares Biotechnology ETF (IBB) decreased 0.5%. In corporate news, Biogen (BIIB) shares fell nearly 6% after the firm said Thursday that a phase 2 trial of diranersen in people with early Alzheimer's disease did not meet its primary endpoint. Prestige Consumer Healthcare ( PBH ) reported weaker-than-expected Q4 results and issued 2026 guidance below consensus, with the shortfall driven primarily by supply constraints in Clear Eyes and broader execution pressures, Oppenheimer said in a note. Oppenheimer downgraded the stock to perform from outperform and removed its $65 price target. Prestige shares slumped past 8%. Doximity ( DOCS ) could face near-term pressure from slowing growth after issuing weaker-than-expected guidance, though strong user engagement trends and expanding AI opportunities continue to support the stock's long-term outlook, Morgan Stanley said in a note. Morgan Stanley lowered the price target on Doximity ( DOCS ) to $35 from $49, while maintaining an overweight rating. Doximity ( DOCS ) shares dropped more than 24%. Aveanna Healthcare ( AVAH ) shares jumped 11% after it reported higher fiscal Q1 adjusted earnings and revenue, and raised its fiscal 2026 revenue guidance. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited. ### Related Stocks - [AVAH.US](https://longbridge.com/en/quote/AVAH.US.md) - [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md) - [DOCS.US](https://longbridge.com/en/quote/DOCS.US.md) - [PBH.US](https://longbridge.com/en/quote/PBH.US.md) - [LGHT.US](https://longbridge.com/en/quote/LGHT.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IHF.US](https://longbridge.com/en/quote/IHF.US.md) - [IYH.US](https://longbridge.com/en/quote/IYH.US.md) - [XHE.US](https://longbridge.com/en/quote/XHE.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md) - [IHI.US](https://longbridge.com/en/quote/IHI.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XHS.US](https://longbridge.com/en/quote/XHS.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [HEAL.US](https://longbridge.com/en/quote/HEAL.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) ## Related News & Research - [TD Cowen Sticks to Their Buy Rating for Biogen (BIIB)](https://longbridge.com/en/news/286442023.md) - [Prestige Consumer Healthcare: Buy Rating Reaffirmed Despite Soft Outlook, with Acquisitions and Undervalued Earnings Power Seen as Upside Drivers](https://longbridge.com/en/news/286324184.md) - [Biogen to advance experimental Alzheimer’s drug despite mid-stage trial miss](https://longbridge.com/en/news/286407083.md) - [BUZZ-Street View: Skeptical on experimental Alzheimer's drug, awaits full data](https://longbridge.com/en/news/286558948.md) - [UnitedHealth Group Incorporated $UNH Holdings Boosted by GSA Capital Partners LLP](https://longbridge.com/en/news/286878927.md)